Navigation Links
TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Date:5/14/2009

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The current clinical trial is being conducted at six centers in the USA. The study enrolled 28 patients in the dose-escalation phase (completed in February 2009) and 31 patients in the dose-confirmation phase of the study (currently in progress). Primary goals of this open-label study included identification of a maximum tolerated dose (MTD) in the dose-escalation phase and accumulation of safety data, assessments of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints in both phases of the study. Preliminary trial data presented at the 2008 ASH conference indicated that the drug was well tolerated and exhibited dose-dependant reductions of splenomegaly and leukocytosis. Updated clinical data pertaining to this trial are scheduled for presentation at the European Hematology Association (EHA) conference on June 6, 2009 in Berlin.

www.targegen.com

About TargeGen, Inc.

TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors for applications in oncology and inflammatory diseases.


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
4. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
5. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Tris Pharma Announces Acceptance of Its First Two NDAs
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
10. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
11. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  ADM Tronics Unlimited, Inc. (OTCQB: ... to its corporate Advisory Board for business development. ... the Harvard Medical School and Visiting Professor at ... his Masters degree in Electronics Engineering and his ... of Bologna. After spending a year as a ...
(Date:9/18/2014)... 18, 2014  ePharmaSolutions, the leading provider ... the Disruptive Innovator of the Year at ... platform. This solution includes an integrated clinical ... (eTMF), a remote monitoring application, eSource and ... screening and matching technology. The ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... United Arab Emirates, Sept. 22 NewBridge Pharmaceuticals announced ... agreement with Orexo AB (STO: ORX) that grants NewBridge ... treatment of breakthrough cancer pain, in the Middle East ... and sell the product in these territories.  The agreement ...
... Decision Resources, one of the world,s leading research and ... to generic erosion of key agents, the colorectal cancer drug ... from more than $6.4 billion in 2009 to just under ... Italy, Spain, United Kingdom and Japan. The Pharmacor ...
Cached Medicine Technology:NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 2NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 3NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 4Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019 2Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019 3
(Date:9/18/2014)... September 18, 2014 According to a new ... Services Market - Global Industry Analysis, Size, Share, Growth, Trends ... services market was valued at USD 77607.7 million in 2013 ... from 2014 to 2020, to reach an estimated value of ... and services market is growing at a rapid pace due ...
(Date:9/18/2014)... September 18, 2014 The new ... boon to contractors and homeowners alike as it ... overtakes the home, causes potential health issues, and ... nationwide, the BuildClean system allows contractors to virtually ... and other standard remodeling tasks. , BuildClean removes ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical ... — EV™ for physicians — improving ... best-of-breed solutions, Holyoke chose T-System’s solution because not ... and reimbursement, but also its ability to integrate ... used to capture emergency department, (ED) nurse documentation. ...
(Date:9/18/2014)... the popular online supplier of funny figurines, has added a ... line. Moreover, all the company’s products are now offered with ... special offer before September 29, 2014. Customers who place bulk ... bobblehead doll ). , “We are pleased to ... make our interesting items available to all the global customers. ...
(Date:9/18/2014)... How much is a serving? , Most ... to the obesity epidemic in the United States. ... to manage portion size during the next “Healthy Eating ... House, 755 Ohltown Road, Austintown. , Registered dietician and ... and answer questions from 12:30 to 2 p.m. Oct. ...
Breaking Medicine News(10 mins):Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:Discounted Custom Bobbleheads Online For Sale At WowBobble.com 2Health News:HMHP Workshop Addresses Portion Control 2
... N.Y. study finds that weather warmer than 75 degrees poses ... research suggests that cocaine overdose deaths in New York City ... average weekly temperature goes past 75 degrees Fahrenheit. , ... Addiction , are based on death statistics in the city ...
... Researchers say defibrillators can be turned off on admission, ... care for people who are dying often forget to ... research has found. , Only 20 percent of more ... that they had a question on their admitting form ...
... , ... ... ... ...
... ... ... , ... , , , ...
... new study, led by researchers at the Herbert Irving ... demonstrates that acupuncture may be an effective therapy for ... are being treated with commonly used hormonal therapies. Results ... . Joint pain and stiffness are common side ...
... it possible to build supercomputers that can replicate the ... to an implantable chip for interfacing with neurons and ... nanoscience and neuroscience are now advancing each other in ... what this means was the topic of an hour-long ...
Cached Medicine News:Health News:Hearts of Hospice Patients Being Needlessly Shocked 2Health News:Hearts of Hospice Patients Being Needlessly Shocked 3Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 2Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 4Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 5Health News:Acupuncture may relieve joint pain caused by some breast cancer treatments 2
Inquire...
Inquire...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
Medicine Products: